Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.25.1 (
proteasome
)
28,817
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Previously, we found a novel gene,
nuclear receptor interaction protein
(
NRIP
), a transcription cofactor that can enhance an AR-driven PSA promoter activity in a ligand-dependent manner in prostate cancer cells. Here, we investigated
NRIP
regulation. We cloned a 413-bp fragment from the transcription initiation site of the
NRIP
gene that had strong promoter activity, was TATA-less and GC-rich, and, based on DNA sequences, contained one androgen response element (ARE) and three Sp1-binding sites (Sp1-1, Sp1-2, Sp1-3). Transient promoter luciferase assays, chromatin immunoprecipitation and small RNA interference analyses mapped ARE and Sp1-2-binding sites involved in
NRIP
promoter activation, implying that
NRIP
is a target gene for AR or Sp1. AR associates with the
NRIP
promoter through ARE and indirectly through Sp1-binding site via AR-Sp1 complex formation. Thus both ARE and Sp1-binding site within the
NRIP
promoter can respond to androgen induction. More intriguingly,
NRIP
plays a feed-forward role enhancing AR-driven
NRIP
promoter activity via
NRIP
forming a complex with AR to protect AR protein from
proteasome
degradation. This is the first demonstration that
NRIP
is a novel AR-target gene and that
NRIP
expression feeds forward and activates its own expression through AR protein stability.
...
PMID:Nuclear receptor interaction protein, a coactivator of androgen receptors (AR), is regulated by AR and Sp1 to feed forward and activate its own gene expression through AR protein stability. 1798 71